Scottish HTA Body Prepares For ‘Conditional Yes’ On Certain New Drugs
Executive Summary
Scotland’s HTA body, the Scottish Medicines Consortium, is about to embark on a new system allowing it to give a “conditional yes” to medicines for which data may be limited at the time of marketing authorization. At the same time, changes are being implemented to the system for allowing patient access to drugs that have not been recommended by the SMC.
You may also be interested in...
Scotland To Improve Early Patient Access to ‘Ultra-Orphan’ Drugs
Scotland is changing that way that medicines for very rare diseases are assessed by the health technology assessment body, the SMC. The changes include a new definition of “ultra-orphan medicine” and a new system for provisionally funding such products while more evidence is gathered on their effectiveness
AstraZeneca On Bridging The Gap Between Accelerated Approval And HTA Requirements
Health technology assessment agencies are struggling to evaluate drugs on the basis of evidence generated for early approvals, says AstraZeneca.
How Scotland Plans To Improve Access To Drugs For Very Rare Diseases
Scotland is to change the way it appraises new drugs for very rare diseases for use on the National Health Service, with a new “conditional yes” option for the Scottish Medicines Consortium that will require further evidence-gathering and subsequent reassessment, and a new appraisal procedure for “true ultra-orphan drugs” for very rare conditions where a cost-benefit assessment may not be appropriate. There will also be provision for earlier engagement on orphan drug pricing with the pharmaceutical industry and for more patient involvement in the SMC’s processes.